Avorn, Jerry <br/><br/>
Evaluating drug effects in the post-Vioxx world: there must be a better way.  [electronic resource] 

 -  Circulation  May 2006 
 - 2173-6 p.  digital 
<br/><br/> Publication Type: Comment; Editorial 
<br/><br/><label>ISSN: </label>1524-4539 
<br/><br/><label>Standard No.: </label>10.1161/CIRCULATIONAHA.106.625749  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anti-Inflammatory Agents, Non-Steroidal--adverse effects<br/>Clinical Trials as Topic--standards<br/>Cyclooxygenase 2 Inhibitors--adverse effects<br/>Drug Approval--legislation & jurisprudence<br/>Drug Costs<br/>Drug and Narcotic Control--legislation & jurisprudence<br/>Duty to Warn--legislation & jurisprudence<br/>Humans<br/>Information Dissemination<br/>Lactones--adverse effects<br/>Myocardial Infarction--chemically induced<br/>Probability<br/>Product Surveillance, Postmarketing--standards<br/>Research Design<br/>Risk Assessment<br/>Stroke--chemically induced<br/>Sulfones--adverse effects<br/>Treatment Outcome<br/>United States<br/>United States Food and Drug Administration